Clinical Trials Browser

HER2-negative Breast Cancer × Paclitaxel × Other solid neoplasm × Clear all

NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 1/2 Active not recruiting

BreastOther solid neoplasm

HER2-negative Breast Cancer